<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773822</url>
  </required_header>
  <id_info>
    <org_study_id>2018/05</org_study_id>
    <nct_id>NCT03773822</nct_id>
  </id_info>
  <brief_title>Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.</brief_title>
  <acronym>COCCA</acronym>
  <official_title>Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled trial is to evaluate the hemodynamic effect of low
      dose corticosteroid therapy (hydrocortisone and fludrocortisone) in the treatment of adult
      cardiogenic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock is a serious condition with a high mortality rate, characterized by acute
      dysfunction of the heart pump. Critical illness-related corticosteroid insufficiency is a
      pathophysiological concept, first described in septic shock. It is characterized by an
      impairment of the hypothalamic pituitary axis during critical illness. Its diagnosis is
      usually suggested by an inappropriate response to the adrenal stimulation test. The results
      of corticosteroid supplementation studies in septic shock are controversial, but most of
      these studies demonstrate that corticosteroid therapy improves reversal of shock.

      The concept of critical illness-related corticosteroid insufficiency has recently been
      expanded to cardiogenic shock. The latter has many physiopathological similarities with
      septic shock. However, no studies have evaluated the effect of supplemental corticosteroid
      supplementation in cardiogenic shock.

      The purpose of this study is to evaluate the hemodynamic effect of low dose corticosteroid
      therapy in the treatment of adult cardiogenic shock.

      This study is a multicenter, randomized, double blinded, placebo controlled trial comparing
      intravenous hydrocortisone (50 mg intravenously every 6 hours) plus enteral fludrocortisone
      (50 µg/day) with placebo for seven days in critically ill patients with cardiogenic shock.

      The primary endpoint for this trial will be catecholamine-fee days at day-7. Secondary
      endpoints will include all-cause mortality at 28 and 90 days after randomisation.

      Several pre-defined sub-groups analyses are planned, including: postcardiotomy, myocardial
      infarction, etomidate use, vasopressor use...

      380 patients will be enrolled in this study at approximately 20 study sites. Each patient
      will be followed-up for 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2019</start_date>
  <completion_date type="Anticipated">July 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients not treated with corticosteroids at day 7</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 28 and 90 days after randomisation</measure>
    <time_frame>28 and 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the cardiac index</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care and hospital</measure>
    <time_frame>28 and 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of support by catecholamines</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of lactatemia</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients use of mechanical ventilation</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Circulatory assistance</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive at day 7 without failure (SOFA) score)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with nosocomial infection</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of patients requiring the introduction of intravenous insulin therapy after randomization</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of mean arterial pressure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Placebo of hydrocortisone and placebo of fludrocortisone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of hydrocortisone + fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydrocortisone + Flucortac</intervention_name>
    <description>Low dose steroids</description>
    <arm_group_label>Combination of hydrocortisone + fludrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo of hydrocortisone and placebo of fludrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged ≥18 years

          2. Cardiogenic shock state, according to the consensual definition:

               1. Systemic arterial hypertension (systolic blood pressure &lt;90 mmHg or mean arterial
                  pressure ≤ 65 mmHg) or signs of peripheral hypoperfusion, requiring treatment
                  with catecholamines to maintain systolic blood pressure ≥ 90 mmHg and regression
                  of signs of hypoperfusion;

               2. Presence of at least one sign of systemic hypoperfusion among the following:
                  marbling, oliguria ≤ 25 ml / h, impairment of consciousness, arterial
                  hyperlactatemia&gt; 2 mmol / L;

               3. Presence of at least one sign of hypocontractility or low flow among the
                  following: cardiac index ≤ 2.2 L / min / m2, left ventricular ejection fraction
                  (LVEF) ≤ 40% or full time velocity (ITV) under aortic ≤ 18 cm, or need for
                  catecholamines to maintain an index

               4. Clinical signs of right or pulmonary congestion or elevation of filling pressures
                  as measured by Doppler (E / A&gt; 2 if FEVG ≤40% or E / Ea&gt; 13 if LVEF&gt; 40% or PAPS&gt;
                  35mmHg) or right heart catheterization (pulmonary artery occlusion pressures&gt;
                  15mmHg or PAPm&gt; 25mmHg) as recommended

          3. Having received informed information about the study and having signed a consent to
             participate in the study

          4. Benefiting from a social security

        Exclusion Criteria:

          1. Cardiogenic shock state with catecholamine infusion for more than 24 hours;

          2. Presence Presence of septic shock at inclusion;

          3. Cardiopulmonary arrest recovered within days (7 days) prior to inclusion;

          4. Patients already on circulatory support (ECMO) before inclusion (patients who are
             assisted after inclusion will not be excluded);

          5. Cardiogenic shock on viral myocarditis;

          6. Prior corticosteroid therapy (≥ 30 mg prednisone or equivalent ≥ 1 month);

          7. Receiving one of the following treatments: ketoconazole, rifampicin, phenytoin,
             phenobarbital, cyclosporine and clarithromycin;

          8. Known history of hypersensitivity to fludrocortisone or hydrocortisone;

          9. Known pregnancy or breastfeeding;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Armand MEKONTSO DESSAP, MD</last_name>
    <phone>(+33)1 46 25 24 33</phone>
    <email>armand.dessap@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François BAGATE,, MD</last_name>
    <phone>(+33)1 49 81 23 89</phone>
    <email>francois.bagate@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François BAGATE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <state>Le Chasnay</state>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal de Villeneuve Saint Georges</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <state>Villeneuve Saint Georges</state>
        <zip>94190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de Marne la Vallée - Site Jossigny</name>
      <address>
        <city>Jossigny</city>
        <zip>77600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Institut Cœur Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud-de-Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CMC Ambroise Paré</name>
      <address>
        <city>Neuilly sur seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre SQUARA, MD</last_name>
      <phone>0146415079</phone>
      <email>recherche@clinique-a-pare.fr</email>
    </contact>
    <contact_backup>
      <last_name>Messaouda MERZOUG, PhD</last_name>
      <email>recherche@clinique-a-pare.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre SQUARA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe ESTAGNASIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BRUSSET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Driss LAGHLEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre cardiologique du nord saint denis</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan MORICHAU-BEAUCHANT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clément DELMAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpitaux de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Steroids</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Fludrocortisone</keyword>
  <keyword>Reversal of shock</keyword>
  <keyword>Mortality</keyword>
  <keyword>Adrenal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

